



Food and Agriculture
Organization of the
United Nations



Foot-and-Mouth Disease

July–September 2020
Quarterly report

FAST Reports

Foot-and-mouth And Similar Transboundary animal diseases

European Commission for the
Control of Foot-and-Mouth Disease

Required citation:

FAO. 2020. *Food-and-mouth disease, July–September 2020: Quarterly report*. FAST reports: Foot-and-mouth and similar transboundary animal diseases. Rome.

The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by FAO in preference to others of a similar nature that are not mentioned.

The views expressed in this information product are those of the author(s) and do not necessarily reflect the views or policies of FAO.

© FAO, 2020



Some rights reserved. This work is made available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo/legalcode>).

Under the terms of this licence, this work may be copied, redistributed and adapted for non-commercial purposes, provided that the work is appropriately cited. In any use of this work, there should be no suggestion that FAO endorses any specific organization, products or services. The use of the FAO logo is not permitted. If the work is adapted, then it must be licensed under the same or equivalent Creative Commons licence. If a translation of this work is created, it must include the following disclaimer along with the required citation: "This translation was not created by the Food and Agriculture Organization of the United Nations (FAO). FAO is not responsible for the content or accuracy of this translation. The original [Language] edition shall be the authoritative edition."

Disputes arising under the licence that cannot be settled amicably will be resolved by mediation and arbitration as described in Article 8 of the licence except as otherwise provided herein. The applicable mediation rules will be the mediation rules of the World Intellectual Property Organization <http://www.wipo.int/amc/en/mediation/rules> and any arbitration will be conducted in accordance with the Arbitration Rules of the United Nations Commission on International Trade Law (UNCITRAL).

Copies of all the individual reports cited herein can be obtained from The Pirbright Institute and the EuFMD and prior to presentation, publication or any other public use of these data, please contact Dr Donald King, The Pirbright Institute, fmd.website@pirbright.ac.uk and eufmd@fao.org

Third-party materials. Users wishing to reuse material from this work that is attributed to a third party, such as tables, figures or images, are responsible for determining whether permission is needed for that reuse and for obtaining permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Sales, rights and licensing. FAO information products are available on the FAO website (www.fao.org/publications) and can be purchased through publications-sales@fao.org. Requests for commercial use should be submitted via: www.fao.org/contact-us/licence-request. Queries regarding rights and licensing should be submitted to: copyright@fao.org.

CONTENTS

1.	Highlights and headlines	3
2.	General overview	4
3.	Summary of FMD outbreaks and intelligence	5
3.1.	Global overview of samples received and tested	5
3.2.	Pool 1 (Southeast Asia/Central Asia/East Asia).....	5
3.3.	Pool 2 (South Asia)	6
3.4.	Pool 3 (West Eurasia and Middle East)	6
3.5.	Pool 4 (North and Eastern Africa)	6
3.6.	Pool 5 (West/Central Africa)	6
3.7.	Pool 6 (Southern Africa)	7
3.8.	Pool 7 (South America).....	7
3.9.	Extent of global surveillance	8
4.	Detailed analysis	11
4.1.	Pool 1 (Southeast/Central/East Asia).....	11
4.2.	Pool 3 (West Eurasia and Middle East)	12
4.3.	Pool 6 (Southern Africa)	15
4.4.	Vaccine matching	16
Annex 1:	Sample data	19
	Summary of submissions	19
	Clinical samples.....	19
Annex 2:	FMD publications	21
Annex 3:	Vaccine recommendations	26
Annex 4:	Brief round-up of EuFMD and WRLFMD activities	27
	Open Session of the EuFMD OS20.....	27
	Courses	27
	Podcasts.....	29
	Meetings.....	29
	Proficiency test scheme organised by WRLFMD	29

Abbreviations and acronyms

BVI	Botswana Vaccine Institute
EIDRA	Emerging Infectious Disease Research Association
EuFMD	European Commission for the Control of Foot-and-Mouth Disease
FAST reports	Foot-and-mouth and similar transboundary animal diseases reports
FGBI “ARRIAH”	Federal Governmental Budgetary Institution “Federal Centre for Animal Health”
FMD	Foot-and-mouth disease
FMDV	Foot-and-mouth disease virus
FMDV GD	Foot-and-mouth disease virus genome detected
FMDV NGD	Foot-and-mouth disease virus genome not detected
GF-TAD	Global Framework for the Progressive Control of Transboundary Animal Diseases
LVRI	The National Reference Laboratory for FMD, The Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
MEVAC	International Facility for Veterinary Vaccines Production (Egypt)
NT	Not tested
NVD	No virus detected
OIE	World Organisation for Animal Health
PIADC	Plum Island Animal Disease Center
rRT-PCR	Real-time reverse transcription polymerase chain reaction
SAARC	South Asian Association for Regional Cooperation
SADC	Southern Africa in collaboration with the Southern African Development Community
SAT	Southern African Territories
SEACFMD	South-East Asia and China FMD campaign
SSARRL	Sub-Saharan Africa Regional Reference Laboratory
SVD	Swine vesicular disease
VETBIS	Veterinary Information System of Turkey
VI	Virus isolation
WAHIS	World Animal Health Information System (of the OIE)
WRLFMD	World Reference Laboratory for Foot-and-Mouth Disease

1. Highlights and headlines

A warm welcome to the third issue of the foot-and-mouth disease (FMD) Quarterly Report. In common with the previous issue, samples submitted to the World Reference Laboratory for Foot-and-Mouth Disease (WRLFMD) during this reporting period (April to June 2020) remain very low. Although it is perhaps inevitable that the international activities of FMD reference laboratories have been impacted by COVID-19, at Pirbright our experience is that air-freight shipments can still be arranged - if they are carefully planned, in advance! We are very happy to be contacted to help address any problems that scientists are experiencing to send samples to WRLFMD for analyses.

In this report, we describe results for foot-and-mouth disease virus (FMDV)-positive samples submitted from Viet Nam, where three different serotype O lineages were detected (O/ME-SA/Ind-2001e, O/ME-SA/PanAsia and O/SEA/Mya-98). Sequence data submitted from Turkey (from GenBank) and Zambia (from SSARRL for FMD, Botswana) were also analysed. In addition to three phylogenetic trees presented in this report that reconstruct the spread of the A/ASIA/G-VII lineage in Turkey during 2015-17, more recent data (received in October from the ŞAP FMD Institute, Ankara) highlights a new introduction of the O/ME-SA/PanAsia-2^{ANT-10} lineage into the country (for the first time since 2017). Elsewhere, there have been reports to the World Organisation for Animal Health (OIE) of outbreaks in South Africa (serotype SAT 2), Libya (serotype A), Rwanda (Kayonza; where serotype SAT 2 has been detected by serology), Mozambique (untyped), and southern Malawi (initially reported as untyped – but now typed as SAT 2 by SSARRL, Botswana). Despite the technical challenges of connecting to virtual platforms (via SKYPE, Zoom etc...), a number of international FMD meetings have been scheduled including the National Coordinators of South-East Asia and China FMD campaign (SEACFMD) during July and the Southern Africa in collaboration with the Southern African Development Community (SADC) FMD Roadmap meeting in November. In December, the Annual meeting of the OIE/Food and Agriculture Organization of the United Nations (FAO) FMD Laboratory Network and the Open Session of the European Commission for the Control of Foot-and-Mouth Disease (EuFMD) will also be held in a virtual-remote format. Finally, I take this opportunity to let FMD colleagues know that WRLFMD and EuFMD will be running an v-learning training course the covers FMD diagnostics starting in November. This course is designed for personnel working in national FMD laboratories and further details are provided in Annex 4 of this report.

Don King, Pirbright October 2020




Figure 1: Recent headline events (reported during July to September 2020) with endemic pools highlighted in orange. Source: WRLFMD. Map conforms to the United Nations World Map, February 2020.

2. General overview

Endemic Pools represent independently circulating and evolving foot-and-mouth disease virus (FMDV) genotypes; within the pools, cycles of emergence and spread occur that usually affect multiple countries in the region. In the absence of specific reports, it should be assumed that the serotypes indicated below are continuously circulating in parts of the pool area and would be detected if sufficient surveillance was in place.

POOL	REGION/COUNTRIES	SEROTYPES PRESENT
	<u>SOUTHEAST ASIA/CENTRAL ASIA/EAST ASIA</u>	
1	Cambodia, China, China (Hong Kong SAR), Taiwan Province of China, Democratic People's Republic of Korea, Republic of Korea, Lao People's Democratic Republic, Malaysia, Mongolia, Myanmar, Russian Federation, Thailand, Viet Nam	A, Asia 1 and O
	<u>SOUTH ASIA</u>	
2	Bangladesh, Bhutan, India, Mauritius, Nepal, Sri Lanka	A, Asia 1 and O
	<u>WEST EURASIA & MIDDLE EAST</u>	
3	Afghanistan, Armenia, Azerbaijan, Bahrain, Georgia, Iran (Islamic Republic of), Iraq, Israel, Jordan, Kazakhstan, Kuwait, Kyrgyzstan, Lebanon, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Syrian Arab Republic, Tajikistan, Turkey, Turkmenistan, United Arab Emirates, Uzbekistan	A, Asia 1 and O (SAT 2)*
	<u>NORTH AFRICA</u>	
	Algeria, Egypt, Libya, Morocco, Tunisia	A, O and SAT 2
4	<u>EASTERN AFRICA</u>	
	Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Rwanda, Somalia, South Sudan, Sudan, Uganda, United Republic of Tanzania, Yemen	O, A, SAT 1, SAT 2 and SAT 3
	<u>WEST/CENTRAL AFRICA</u>	
5	Benin, Burkina Faso, Cabo Verde, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Sao Tome and Principe, Senegal, Sierra Leone, Togo	O, A, SAT 1 and SAT 2
	<u>SOUTHERN AFRICA</u>	
6	Angola, Botswana, Malawi, Mozambique, Namibia, South Africa, Zambia, Zimbabwe	SAT 1, SAT 2 and SAT 3 (O, A) [†]
	<u>SOUTH AMERICA</u>	
7	Colombia, Venezuela (Bolivarian Republic of)	O and A

* Reported only in Oman in 2017

[†] only in Angola and north Zambia as spill-over from pool 4

3. Summary of FMD outbreaks and intelligence

3.1. Global overview of samples received and tested

The location of all samples detailed in this report can be seen on the map below. More detailed maps and sample data, on a country by country basis, can be found in the following sections of this report.





Figure 1: Samples tested by WRLFMD or reported in this quarter. ● indicates samples analysed; × indicates new outbreaks reported to the OIE, but where results to define the genotype have not been reported; □ indicates reports of FMD from other sources. Shape colours define the serotype detected ●O; ●A; ●C; ●Asia1, ●SAT1, ●SAT2, ●SAT3, ○ FMD not detected, ● serotype undetermined/not given in the report.

Source: WRLFMD. Map conforms to the United Nations World map, February 2020.


3.2. Pool 1 (Southeast Asia/Central Asia/East Asia)

The Socialist Republic of Viet Nam



On the 11 June 2020, a batch of 39 samples (collected between February 2019 and February 2020 from cattle, water buffalo and pigs in various locations across the country) was received by the WRLFMD. **FMD type O** virus was isolated from 29 of the samples, while seven were FMDV-GD and three were NVD. VP1 genotyping identified 21 ME-SA/Ind-2001e, two ME-SA/PanAsia and five SEA/Mya-98, while one sample contained both ME-SA/Ind-2001e and SEA/Mya-98.

The Republic of Indonesia



On 21 July 2020, two serum samples, collected from pigs at the Pig Kapuk Slaughterhouse, Jakarta on 01 May 2019, were received. Vesicular exanthema of swine (caused by a calicivirus) had been suspected. Samples were tested at WRLFMD by rRT-PCR with negative results for FMDV, SVDV and vesicular exanthema of swine virus.

3.3. Pool 2 (South Asia)

No new outbreaks of FMD were reported in the West/Central Africa.

3.4. Pool 3 (West Eurasia and Middle East)

The Republic of Turkey




On 24 August 2020, 56 FMD type A virus VP1 sequences were received from the FMDI-Ankara. The sequences originated from samples collected from cattle in 2015, 2016 and 2017 (no locations were given). Genotyping showed that all belonged to toptype ASIA, lineage G-VII. Phylogenetic trees separated by each year are presented in this report.

[Tuncer-Göktuna *et al.*, 2020](#)

3.5. Pool 4 (North and Eastern Africa)

State of Libya



Four outbreaks of **FMD type A** were reported in sheep at Qasabana Ghashir, Biir Althawthuh, Tarabulus on 06 September 2020.

[OIE Immediate notification & Follow-up reports](#)

The Republic of Rwanda



An outbreak of **FMD type SAT 2** was reported in cattle in various locations of Kayonza District, Eastern Province on 22 June 2020. No genotyping results are available.

[OIE Immediate notification & Follow-up reports](#)

3.6. Pool 5 (West/Central Africa)

No new outbreaks of FMD were reported in the West/Central Africa.

3.7. Pool 6 (Southern Africa)


The Republic of Malawi



An outbreak of FMD (untyped) was reported in cattle at Kasokeza, Maperera Dip tank, Chikwawa, Southern Region on 07 August 2020. No genotyping results are available.

[OIE Immediate notification & Follow-up reports](#)

The Republic of Mozambique



An outbreak of FMD (untyped) was reported in cattle at Sabão, Magude Sede, Magude, Maputo on 10 August 2020. No genotyping results are available.

[OIE Immediate notification & Follow-up reports](#)

The Republic of South Africa



A further outbreak of FMD type SAT 2 was reported in cattle at Bushbuckridge, Mpumalanga on 30 April 2020. No genotyping results are available.

[OIE Immediate notification & Follow-up reports](#)

The Republic of Zambia



On the 28 July 2020, a single **FMD type O** VP1 sequence was received from the BVI. The sequence was derived from a sample collected from cattle in Nalolo district, Western Province on 14 January 2020. Genotyping showed it belonged to the EA-2 toponotype.

3.8. Pool 7 (South America)

No new outbreaks of FMD were reported in South America.

3.9. Extent of global surveillance




Figure 2: Samples received during 2019 from FMD outbreaks (routine surveillance that is undertaken in countries that are FMD-free without vaccination is not shown). Data from presentations given at the OIE/FAO Reference laboratory Network annual meeting (<https://www.foot-and-mouth.org/Ref-Lab-Network/Network-Annual-Meeting>)

Source: WRLFMD. Map conforms to the United Nations World map, February 2020.




Figure 4: Representation of different FMDV serotypes detected in samples tested from the FMD endemic pools by the OIE/FAO FMD Laboratory Network during 2019 (draft data) (NVD = no virus detected; GD = genome detected)

Source: OIE/FAO FMD Laboratory Network, 2019 (draft data).

In regions where FMD is endemic, continuous evolution of the virus generates geographically discrete lineages that are genetically distinct from FMD viruses found elsewhere. This report displays how different FMD lineages circulate in different regions; these analyses accommodate the latest epidemiological intelligence to assess the relative importance of the viral strains circulating within each regions (see Table 1, below).

Table 1: Conjectured relative prevalence of circulating FMD viral lineages in each Pool. For each of the regions, data represent the relative importance of each viral lineage [prevalence score estimated as a percentage (%) of total FMD cases that occur in domesticated hosts]. These scores can be used to inform the PRAGMATIST tool (see Annex 3)

Lineage	Southeast / Central / East Asia [Pool 1]	South Asia [Pool 2]	West Eurasia & Middle East [Pool 3]	North Africa	Eastern Africa [Pool 4]	West / Central Africa [Pool 5]	Southern Africa [Pool 6]	South America [Pool 7]
O ME-SA PanAsia-2			35					
O ME-SA PanAsia	10							
O SEA Mya-98	33							
O ME-SA Ind2001	20	80	6	10				
O EA or O WA			3	55	55	70		
O EURO-SA								80
O CATHAY	10.5							
A ASIA Sea-97	25							
A ASIA Iran-05	0		25.5					
A ASIA G-VII		16	17.5					
A AFRICA				25	22	15		
A EURO-SA								20
Asia-1	1.5	4	12.5					
SAT 1				0	8	5	27	
SAT 2			0.5	10	14	10	57	
SAT 3					1		16	
C								

A number of outbreaks have occurred where samples have not been sent to the WRLFMD or other laboratories in the OIE/FAO FMD Laboratory Network. An up-to-date list and reports of FMD viruses characterised by sequencing can be found at the following website: <http://www.wrlfmd.org/country-reports/country-reports-2020>.

Results from samples or sequences received at WRLFMD (status of samples being tested) are shown in Table 2 and a complete list of clinical sample diagnostics made by the WRLFMD from July to September 2020 is shown in Annex 1: (Summary of submissions). A record of all samples received by WRLFMD is shown in Annex 1: (Clinical samples).

Table 2: Status of sequencing of samples or sequences received by the WRLFMD from July to September 2020 (* indicates a batch carried over from the previous quarter).

WRLFMD Batch No.	Date received	Country	Serotype	No. of samples	No. of sequences	Sequencing status
WRLFMD/2020/00003*	11/06/2020	Viet Nam	pending	29	30 [†]	Completed
Total				29	30	


[†] two different sequences were obtained from one sample.

Table 3: VP1 sequences submitted by other FMD Network laboratories to the WRLFMD from July to September 2020 (* indicates sequences retrieved from GenBank).

WRLFMD Batch No.	Date received	Country	Serotype	Date Collected	No. of sequences	Submitting laboratory
WRLMEG/2020/00022	28/07/2020	Zambia	O	14/01/2020	1	BVI
WRLMEG/2020/00023	24/08/2020	Turkey	A	2015	13	FMDI
WRLMEG/2020/00024	24/08/2020	Turkey	A	2016	13	FMDI
WRLMEG/2020/00025	24/08/2020	Turkey	A	2017	30	FMDI
Total					57	

4. Detailed analysis

4.1. Pool 1 (Southeast/Central/East Asia)



4.2. Pool 3 (West Eurasia and Middle East)

The Republic of Turkey


Batch: WRLMEG/2020/00023
 WRLMEG/2020/00024
 WRLMEG/2020/00025

Date received: 24/08/2020


[Tuncer-Göktuna et al., 2020](#)

No. of sequences: 56

Data for 2015:




Turkey Continued
Data for 2016




Continued on next page

Turkey continued
Data for 2017:



4.3. Pool 6 (Southern Africa)



4.4. Vaccine matching

Antigenic characterisation of FMD field isolates by matching with vaccine strains by 2dmVNT from July to September 2020.

NOTES:


1. Vaccine efficacy is influenced by vaccine potency, antigenic match and vaccination regime. Therefore, it is possible that a less than perfect antigenic match of a particular antigen may be compensated by using a high potency vaccine and by administering more than one vaccine dose at suitable intervals. Thus, a vaccine with a weak antigenic match to a field isolate, as determined by serology, may nevertheless afford some protection if it is of sufficiently high potency and is administered under a regime to maximise host antibody responses (Brehm, 2008).
2. Vaccine matching data generated in this report only considers antibody responses in cattle after a single vaccination (typically 21 days after vaccination). The long-term performance of FMD vaccines after a second or multiple doses of vaccine should be monitored using post-vaccination serological testing.

Table 4: Summary of samples tested by vaccine matching

Serotype	O	A	C	Asia-1	SAT 1	SAT 2	SAT 3
Pakistan	2	4	-	2	-	-	-
Viet Nam	5	-	-	-	-	-	-
Total	7	4	0	2	0	0	0

Abbreviations used in tables

For each field isolate the r1 value is shown followed by the heterologous neutralisation titre (r1-value / titre). The r1 values shown below, represent the one-way serological match between vaccine strain and field isolate, calculated from the comparative reactivity of antisera raised against the vaccine in question. Heterologous neutralisation titres for vaccine sera with the field isolates are included as an indicator of cross-protection.



NOTE: A “0” in the neutralisation columns indicates that for that particular field virus no neutralisation was observed at a virus dose of a 100 TCID₅₀.

NOTE: This report includes the source of the vaccine virus and bovine vaccinal serum. Vaccines from different manufactures may perform differently and caution should be taken when comparing the data.

Table 5: Vaccine matching studies for O FMDV by VNT (*VIT/13/2019 contains both SEA/Mya-98 and ME-SA/Ind-2001e) –

Strain	Serotype O		O 3039		O ₁ Manisa		O/TUR/5/2009	
	Topotype	Lineage	Boehringer Ingelheim <i>R₁</i>	<i>Titre</i>	Boehringer Ingelheim <i>R₁</i>	<i>Titre</i>	MerckAnimal Health <i>R₁</i>	<i>Titre</i>
PAK 46/2019	ME-SA	Ind-2001	0.37	1.54	0.4	1.94	0.54	1.84
VIT/13/2020	ME-SA	Ind-2001	0.46	1.64	0.48	1.98	0.71	1.98
VIT/19/2019	ME-SA	PanAsia	0.6	1.76	0.59	2.07	0.87	2.07
PAK 3/2020	ME-SA	PanAsia-2	0.55	1.71	0.4	1.94	0.98	2.10
VIT/13/2019*	SEA	Mya-98	0.36	1.52	0.19	1.58	0.34	1.71
	ME-SA	Ind-2001						
VIT/15/2019	SEA	Mya-98	0.26	1.40	0.23	1.66	0.39	1.72
VIT/31/2019	SEA	Mya-98	0.37	1.51	0.25	1.68	0.37	1.80

Table 6: Vaccine matching studies for A FMDV by VNT

Strain	Serotype A		A/IRN/05 Boehringer Ingelheim		A/TUR/20/06 MerckAnimal Health		A22/IRQ Boehringer Ingelheim	
	<i>Topotype</i>	<i>Lineage</i>	<i>R₁</i>	<i>Titre</i>	<i>R₁</i>	<i>Titre</i>	<i>R₁</i>	<i>Titre</i>
PAK/30/2016	ASIA	Iran-05	0.60	2.23	0.50	1.58	0.47	2.00
PAK/73/2019	ASIA	Iran-05	0.93	2.45	0.23	1.25	0.68	2.16
PAK/01/2020	ASIA	Iran-05	0.14	1.64	0.17	1.11	0.37	1.90
PAK/02/2020	ASIA	Iran-05	0.07	1.30	0.00	0.00	0.09	1.26

Table 7: Vaccine matching studies for Asia-1 FMDV by VNT

Strain	Serotype Asia-1		Shamir Boehringer Ingelheim	
	<i>Topotype</i>	<i>Lineage</i>	<i>R₁</i>	<i>Titre</i>
PAK/32/2016	Sindh-08		0.18	1.72
PAK/75/2019	Sindh-08		0.50	2.16

Annex 1: Sample data

Summary of submissions

Table 8: Summary of samples collected and received to WRLFMD (July to September 2020)

Country	N ^o of samples	Virus isolation in cell culture/ELISA								No Virus Detected	RT-PCR for FMD	
		FMD virus serotypes							Positive		Negative	
		O	A	C	SAT 1	SAT 2	SAT 3	ASIA-1				
The Republic of Indonesia	2	-	-	-	-	-	-	-	-	0	2	
The Socialist Republic of Viet Nam*	39	19	-	-	-	-	-	-	20	36	3	
TOTAL	41	19	0	0	0	0	0	9	20	36	5	

* Batch received in previous quarter

† Batch received for vesicular exanthema of swine virus (VESV) testing. These samples were also tested for FMDV.

Clinical samples

Table 9: Clinical sample diagnostics made by the WRLFMD® July to September 2020

Country	Date		WRL for FMD Sample Identification	Animal	Date of Collection	Results		
	Received	Reported				VI/ELISA	RT-PCR	Final report
The Republic of Indonesia	21 Jul. 2020	28 Jul. 2020	ISA 1/2019	Pig	01/05/2019	Not Tested	NEG	FMDV NGD
			ISA 2/2019	Pig	01/05/2019	Not Tested	NEG	FMDV NGD
The Socialist Republic of Viet Nam	11 Jun. 2020	3 Jul. 2020	VIT 12/2019	Pig	26/02/2019	O	POS	O
			VIT 13/2019	Pig	27/02/2019	O	POS	O
			VIT 14/2019	Pig	15/03/2019	NEG	POS	FMDV GD
			VIT 15/2019	Pig	19/03/2019	O	POS	O
			VIT 16/2019	Pig	31/03/2019	NEG	POS	FMDV GD
			VIT 17/2019	Pig	20/05/2019	O	POS	O
			VIT 18/2019	Pig	26/07/2019	NEG	POS	FMDV GD
			VIT 19/2019	Buffalo	28/08/2019	O	POS	O
			VIT 20/2019	Buffalo	11/11/2019	O	POS	O
			VIT 21/2019	Cattle	12/11/2019	NEG	POS	FMDV GD
			VIT 22/2019	Cattle	16/11/2019	NEG	POS	FMDV GD
			VIT 23/2019	Buffalo	19/11/2019	NEG	POS	FMDV GD
			VIT 24/2019	Buffalo	24/11/2019	NEG	POS	FMDV GD
			VIT 25/2019	Pig	26/11/2019	O	POS	O
VIT 26/2019	Cattle	26/11/2019	NEG	POS	FMDV GD			

Country	Date		WRL for FMD Sample Identification	Animal	Date of Collection	Results		
	Received	Reported				VI/ELISA	RT-PCR	Final report
			VIT 27/2019	Cattle	28/11/2019	O	POS	O
			VIT 28/2019	Buffalo	30/11/2019	O	POS	O
			VIT 29/2019	Buffalo	03/12/2019	O	POS	O
			VIT 30/2019	Buffalo	04/12/2019	NEG	NEG	NVD
			VIT 31/2019	Cattle	08/12/2019	O	POS	O
			VIT 32/2019	Cattle	11/12/2019	O	POS	O
			VIT 33/2019	Cattle	16/12/2019	NEG	POS	FMDV GD
			VIT 34/2019	Cattle	19/12/2019	NEG	POS	FMDV GD
			VIT 35/2019	Cattle	25/12/2019	NEG	POS	FMDV GD
			VIT 36/2019	Cattle	30/12/2019	NEG	POS	FMDV GD
			VIT 1/2020	Buffalo	07/01/2020	NEG	POS	FMDV GD
			VIT 2/2020	Buffalo	07/01/2020	NEG	POS	FMDV GD
			VIT 3/2020	Cattle	15/01/2020	O	POS	O
			VIT 4/2020	Cattle	20/01/2020	O	POS	O
			VIT 5/2020	Buffalo	20/01/2020	NEG	NEG	NVD
			VIT 6/2020	Cattle	22/01/2020	O	POS	O
			VIT 7/2020	Pig	29/01/2020	O	POS	O
			VIT 8/2020	Cattle	31/01/2020	NEG	NEG	NVD
			VIT 9/2020	Cattle	31/01/2020	O	POS	O
			VIT 10/2020	Cattle	06/02/2020	NEG	POS	FMDV GD
			VIT 11/2020	Cattle	11/02/2020	NEG	POS	FMDV GD
			VIT 12/2020	Cattle	19/02/2020	O	POS	O
			VIT 13/2020	Cattle	25/02/2020	O	POS	O
			VIT 14/2020	Cattle	27/02/2020	NEG	POS	FMDV GD
TOTAL					41			

Annex 2: FMD publications

Recent FMD Publications (July to September 2020) cited by Web of Science.

1. **Abu-Elnaga, H.I., S.A. Rizk, H.M. Daoud, A.A. Mohamed, W. Mossad, M.A. Gamil, A.F. Soudy, & L.I. El-Shehawy.** Comparative nucleotide sequencing of the VP1 capsid gene of recent isolates of Foot-and-mouth disease virus serotype O from Egypt. *Archives of Virology*: 8. DOI: 10.1007/s00705-020-04708-1.
2. **Al Amin, M., M.R. Ali, A. Ul Alam, M.A. Siddique, M.M. Rahaman, M. Sultana, & M.A. Hossain.** Complete genome sequence of a potential *Foot-and-mouth disease virus* serotype O vaccine strain from Bangladesh. *Archives of Virology*: 4. DOI: 10.1007/s00705-020-04711-6.
3. **Al Amin, M., M.R. Ali, M.R. Islam, A. Ul Alam, D.K. Shill, M.S. Rahman, M.A. Siddique, M. Sultana, & M.A. Hossain (2020).** Development and serology based efficacy assessment of a trivalent foot-and-mouth disease vaccine. *Vaccine*, 38(32): 4970-4978. DOI: 10.1016/j.vaccine.2020.05.079.
4. **Aman, E., W. Molla, Z. Gebreegizabher, & W.T. Jemberu (2020).** Spatial and temporal distribution of foot-and-mouth disease outbreaks in Amhara region of Ethiopia in the period 1999 to 2016. *BMC Veterinary Research*, 16(1): 8. DOI: 10.1186/s12917-020-02411-6.
5. **Armson, B., S. Gubbins, V. Mioulet, I.A. Qasim, D.P. King, & N.A. Lyons (2020).** Foot-and-mouth disease surveillance using pooled milk on a large-scale dairy farm in an endemic setting. *Frontiers in Veterinary Science*, 7: 11. DOI: 10.3389/fvets.2020.00264.
6. **Aziz-ul, R., K. Dhama, Q. Ali, M.A. Raza, U. Chaudhry, & M.Z. Shabbir (2020).** Foot-and-mouth disease in a wide range of wild hosts: a potential constraint in disease control efforts worldwide particularly in disease-endemic settings. *Acta Tropica*, 210: 9. DOI: 10.1016/j.actatropica.2020.105567.
7. **Belayneh, N., W. Molla, M. Mesfine, & W.T. Jemberu (2020).** Modeling the transmission dynamics of foot-and-mouth disease in Amhara region, Ethiopia. *Preventive Veterinary Medicine*, 181: 6. DOI: 10.1016/j.prevetmed.2019.04.002.
8. **Bidart, J., C. Kornuta, M. Gammella, V. Gnazzo, I. Soria, C. Langellotti, C. Mongini, R. Galarza, L. Calvino, G. Lupi, V. Quattrocchi, I. Marcipar, & P. Zamorano (2020).** A new cage-like particle adjuvant enhances protection of foot-and-mouth disease vaccine. *Frontiers in Veterinary Science*, 7: 12. DOI: 10.3389/fvets.2020.00396.
9. **Canas-Arranz, R., P. de Leon, M. Forner, S. Defaus, M.J. Bustos, E. Torres, D. Andreu, E. Blanco, & F. Sobrino (2020).** Immunogenicity of a dendrimer B2T peptide harboring a T-cell epitope from FMDV non-structural protein 3D. *Frontiers in Veterinary Science*, 7: 10. DOI: 10.3389/fvets.2020.00498.
10. **Caridi, F., S. Lopez-Arguello, A. Rodriguez-Huete, E. Torres, M.J. Bustos, R. Canas-Arranz, M.A. Martin-Acebes, M.G. Mateu, & F. Sobrino (2020).** Negatively charged amino acids at the foot-and-mouth disease virus capsid reduce the virion-destabilizing effect of viral RNA at acidic pH. *Scientific Reports*, 10(1): 8. DOI: 10.1038/s41598-020-58414-8.
11. **Chen, Y.B., Y. Hu, H.C. Chen, X.M. Li, & P. Qian (2020).** A ferritin nanoparticle vaccine for *foot-and-mouth disease virus* elicited partial protection in mice. *Vaccine*, 38(35): 5647-5652. DOI: 10.1016/j.vaccine.2020.06.063.
12. **Chitray, M., P.A. Opperman, L. Rotherham, J. Fehrsen, W. van Wyngaardt, J. Frischmuth, E. Rieder, & F.F. Maree (2020).** Diagnostic and epitope mapping potential of single-chain antibody fragments against *Foot-and-mouth disease virus* serotypes A, SAT1, and SAT3. *Frontiers in Veterinary Science*, 7: 16. DOI: 10.3389/fvets.2020.00475.
13. **Corbellini, L.G., F. Fernandez, E. Vitale, C.M. Olmos, P. Charbonnier, M.V.I. Barbosa, & F. Riet-Correa (2020).** Shifting to foot-and-mouth disease-free status without vaccination: Application of the PROMETHEE method to assist in the development of a foot-and-mouth

- national program in Uruguay. *Preventive Veterinary Medicine*, **181**: 14. DOI: 10.1016/j.prevetmed.2020.105082.
14. **Cui, X.M., Y. Wang, R. Guan, M.Q. Lu, L.J. Yuan, W. Xu, & S.H. Hu** (2020). Enhanced immune responses with serum proteomic analysis of Hu sheep to foot-and-mouth disease vaccine emulsified in a vegetable oil adjuvant. *Vaccines*, **8**(2): 18. DOI: 10.3390/vaccines8020180.
 15. **de Menezes, T.C., I. Luna, & S.H.G. de Miranda** (2020). Network analysis of cattle movement in Mato Grosso do Sul (Brazil) and implications for Foot-and-mouth disease. *Frontiers in Veterinary Science*, **7**: 17. DOI: 10.3389/fvets.2020.00219.
 16. **Diep, N.V., T.T.B. Ngoc, L.Q. Hoa, B.T.T. Nga, B. Kang, J. Oh, N.T. Lan, & V.P. Le**. O/SEA/Mya-98 lineage *Foot-and-mouth disease virus* was responsible for an extensive epidemic that occurred in late 2018 in Viet Nam. *Archives of Virology*: **7**. DOI: 10.1007/s00705-020-04763-8.
 17. **Firestone, S.M., Y. Hayama, M.S.Y. Lau, T. Yamamoto, T. Nishi, R.A. Bradhurst, H. Demirhan, M.A. Stevenson, & T. Tsutsui** (2020). Transmission network reconstruction for foot-and-mouth disease outbreaks incorporating farm-level covariates. *Plos One*, **15**(7): 17. DOI: 10.1371/journal.pone.0235660.
 18. **Gashirai, T.B., S.D. Hove-Musekwa, & S. Mushayabasa** (2020). Lyapunov stability analysis of a delayed Foot-and-mouth disease model with animal vaccination. *Discrete Dynamics in Nature and Society*, **2020**: 13. DOI: 10.1155/2020/3891057.
 19. **Gizaw, D., Y. Tesfaye, B.A. Wood, A. Di Nardo, D. Shegu, A. Muluneh, T. Bilata, R. Belayneh, A. Fentie, H. Asgdome, M. Sombo, T. Rufael, F.T. Woldemariyam, F. Khan, M. Yami, E. Gelaye, J. Wadsworth, N.J. Knowles, & D.P. King**. Molecular characterization of foot-and-mouth disease viruses circulating in Ethiopia between 2008 and 2019. *Transboundary and Emerging Diseases*: **10**. DOI: 10.1111/tbed.13675.
 20. **Gomez, F., J. Prieto, J. Galvis, F. Moreno, & J. Vargas**, *Identification of Super-Spreaders of Foot-and-mouth disease in the cattle transportation network: The 2018 outbreak case in Cesar (Colombia)*. Proceedings of 2019 IEEE 4th World Conference on Complex Systems, ed. M. Essaïdi and M. Nemiche. 2019, New York: IEEE. 159-164.
 21. **Gray, A.R., B.A. Wood, E. Henry, M. Azhar, D.P. King, & V. Mioulet** (2020). Evaluation of cell lines for the isolation of *Foot-and-mouth disease virus* and other viruses causing vesicular disease. *Frontiers in Veterinary Science*, **7**: 11. DOI: 10.3389/fvets.2020.00426.
 22. **Grazioli, S., N.P. Ferris, G. Dho, G. Pezzoni, A.S. Morris, V. Mioulet, & E. Brocchi**. Development and validation of a simplified serotyping ELISA based on monoclonal antibodies for the diagnosis of *Foot-and-mouth disease virus* serotypes O, A, C and Asia 1. *Transboundary and Emerging Diseases*: **11**. DOI: 10.1111/tbed.13677.
 23. **Hosny, W.A., E.M. Baheeg, H.A. Aly, S.S.A. Nabi, & N.M. Hanna** (2020). Field serological investigation for peste des petits ruminants, foot-and-mouth disease, and bluetongue diseases in illegally introduced animals in Egypt. *Veterinary World*, **13**(8): 1661-1666. DOI: 10.14202/vetworld.2020.1661-1666.
 24. **Hossen, M.L., S. Ahmed, M.F.R. Khan, K. Nazir, S. Saha, M.A. Islam, M.T. Rahman, S.M. Sayem, & M.B. Rahman** (2020). The emergence of *Foot-and-mouth disease virus* serotype O PanAsia-02 sub-lineage of Middle East-South Asian topotype in Bangladesh. *Journal of Advanced Veterinary and Animal Research*, **7**(2): 360-366. DOI: 10.5455/javar.2020.g429.
 25. **Islam, M.R., M.S. Rahman, M. Al Amin, A. Ul Alam, M.A. Siddique, M. Sultana, & M.A. Hossain**. Evidence of combined effect of amino acid substitutions within G-H and B-C loops of VP1 conferring serological heterogeneity in *Foot-and-mouth disease virus* serotype A. *Transboundary and Emerging Diseases*: **10**. DOI: 10.1111/tbed.13687.
 26. **Jiang, F., P.F. Song, J.J. Zhang, Z.Y. Cai, X.W. Chi, H.M. Gao, W. Qin, S.Q. Li, & T.Z. Zhang** (2020). Assessing the impact of climate change on the spatio-temporal distribution of Foot-and-Mouth Disease risk for elephants. *Global Ecology and Conservation*, **23**: 12. DOI: 10.1016/j.gecco.2020.e01176.

27. **Kabelo, T., E. Fana, & K. Lebani** (2020). Assessment of the sensitivity of primary cells and cell lines to the Southern African Territories (SAT) serotypes in the diagnosis of *Foot-and-mouth disease virus*. *Heliyon*, 6(5): 5. DOI: 10.1016/j.heliyon.2020.e03905.
28. **Karniely, S., F. Hamed, B. Gelman, R. King, N. Storm, E. Eyngor, & B.E. Tov** (2020). First isolation of foot-and-mouth disease virus from wild boars in the Middle East. *Transboundary and Emerging Diseases*, 67(4): 1725-1729. DOI: 10.1111/tbed.13507.
29. **Kloc, A., D.K. Rai, D.P. Gladue, E. Schafer, M. Kenney, & E. Rieder** (2020). Residues within the *Foot-and-mouth disease virus* 3D(pol) nuclear localization signal affect polymerase fidelity. *Journal of Virology*, 94(17): 16. DOI: 10.1128/jvi.00833-20.
30. **Lagree, A.C., F. Fasani, C. Rouxel, M. Pivet, M. Pourcelot, A. Fablet, A. Romey, G. Caignard, D. Vitour, S. Blaise-Boisseau, C. Kieda, H.J. Boulouis, N. Haddad, & C. Grillon** (2020). Bovine organospecific microvascular endothelial cell lines as new and relevant *in vitro* models to study viral infections. *International Journal of Molecular Sciences*, 21(15): 24. DOI: 10.3390/ijms21155249.
31. **Lee, M.J., H. Jo, S.H. Park, M.K. Ko, S.M. Kim, B. Kim, & J.H. Park** (2020). Advanced foot-and-mouth disease vaccine platform for stimulation of simultaneous cellular and humoral immune responses. *Vaccines*, 8(2): 22. DOI: 10.3390/vaccines8020254.
32. **Li, S., Y.L. Yang, X. Lin, Z.J. Li, G.H. Ma, Z.G. Su, & S.P. Zhang** (2020). A novel particulate delivery system based on antigen-Zn²⁺ coordination interactions enhances stability and cellular immune response of inactivated *Foot-and-mouth disease virus* shuai. *Molecular Pharmaceutics*, 17(8): 2952-2963. DOI: 10.1021/acs.molpharmaceut.0c00365.
33. **Lim, D.R., H.R. Kim, H.G. Chae, B.K. Ku, J.J. Nah, S. Ryoo, S.H. Wee, C. Lee, Y.S. Lyoo, & C.K. Park**. Probe-based real-time reverse transcription loop-mediated isothermal amplification (RRT-LAMP) assay for rapid and specific detection of *Foot-and-mouth disease virus*. *Transboundary and Emerging Diseases*: 10. DOI: 10.1111/tbed.13669.
34. **Limon, G., G. Ulziibat, B. Sandag, S. Dorj, D. Purevtseren, B. Khishgee, G. Basan, T. Bandi, S. Ruuragch, M. Bruce, J. Rushton, P.M. Beard, & N.A. Lyons**. Socio-economic impact of Foot-and-mouth disease outbreaks and control measures: An analysis of Mongolian outbreaks in 2017. *Transboundary and Emerging Diseases*: 16. DOI: 10.1111/tbed.13547.
35. **Marsot, M., B. Durand, W. Ben Hammouda, H.H. Ammar, M. Zrelli, & R. Khorchani** (2020). Evaluation of human resources needed and comparison with human resources available to implement emergency vaccination in case of foot-and-mouth disease outbreaks in Tunisia. *Epidemiology and Infection*, 148: 8. DOI: 10.1017/s0950268820001284.
36. **Medina, G.N., P. Azzinaro, E. Ramirez-Medina, J. Gutkoska, Y. Fang, F.D.S. Segundo, & T. de los Santos** (2020). Impairment of the deISGylation activity of Foot-and-mouth disease virus Lpro causes attenuation *in vitro* and *in vivo*. *Journal of Virology*, 94(13): 14. DOI: 10.1128/jvi.00341-20.
37. **Medina, G.N., T. de los Santos, & F. Diaz-San Segundo** (2020). Use of IFN-based biotherapeutics to harness the host against foot-and-mouth disease. *Frontiers in Veterinary Science*, 7: 15. DOI: 10.3389/fvets.2020.00465.
38. **Morioka, K., K. Urayama, A. Wada, K. Yoshida, T. Kato, R. Kitano, T. Nishi, T. Kanno, M. Yamada, M. Yamakawa, G. Ulziibat, Y. Makino, K. Nakamura, E. Hojo, T. Matsumoto, & K. Fukai** (2020). Development and evaluation of silver amplification immunochromatography kit for *Foot-and-mouth disease virus* antigen detection (vol 275C, 113736, 2019). *Journal of Virological Methods*, 280: 3. DOI: 10.1016/j.jviromet.2020.113860.
39. **Muthukrishnan, M., N.S. Balasubramanian, & S.V. Alwar** (2020). Experimental infection of foot-and-mouth disease in Indian sheep and goats. *Frontiers in Veterinary Science*, 7: 7. DOI: 10.3389/fvets.2020.00356.
40. **Orton, R.J., C.F. Wright, D.P. King, & D.T. Haydon** (2020). Estimating viral bottleneck sizes for FMDV transmission within and between hosts and implications for the rate of viral evolution. *Interface Focus*, 10(1): 10. DOI: 10.1098/rsfs.2019.0066.

41. **Pak, S.I., G. Lee, M. Sin, H. Park, & J. Park.** Identifying high-risk areas of Foot-and-mouth disease outbreak using a spatiotemporal score statistic: a case of South Korea. *International Regional Science Review*: 24. DOI: 10.1177/0160017620931581.
42. **Poudel, U., U. Dahal, N. Upadhyaya, S. Chaudhari, & S. Dhakal** (2020). Livestock and poultry production in Nepal and current status of vaccine development. *Vaccines*, 8(2): 9. DOI: 10.3390/vaccines8020322.
43. **Pulido, M.R., E. Martinez-Salas, F. Sobrino, & M. Saiz** (2020). MDA5 cleavage by the Leader protease of *Foot-and-mouth disease virus* reveals its pleiotropic effect against the host antiviral response. *Cell Death & Disease*, 11(8): 13. DOI: 10.1038/s41419-020-02931-x.
44. **Pulido, M.R., H.B. Ranjitha, & M. Saiz** (2020). A wide-ranging antiviral response in wild boar cells is triggered by non-coding synthetic RNAs from the *Foot-and-mouth disease virus* genome. *Frontiers in Veterinary Science*, 7: 7. DOI: 10.3389/fvets.2020.00495.
45. **Rahman, A., S.K.S. Islam, M. Abu Sufian, M.H. Talukder, M.P. Ward, & B. Martinez-Lopez** (2020). Foot-and-mouth disease space-time clusters and risk factors in cattle and buffalo in Bangladesh. *Pathogens*, 9(6): 14. DOI: 10.3390/pathogens9060423.
46. **Reddy, B.S. & S. Sivajothi** (2020). Analysis of the stress and haematological changes after foot-and-mouth disease vaccination in buffaloes. *Buffalo Bulletin*, 39(2): 155-159.
47. **Ren, T.T., Y.X. Wang, H.T. Chen, K.L. Wang, X. Gao, L. Liu, Y.G. Zhang, & Y.F. Sun** (2020). MicroRNA-4331-5p promotes FMDV replication through inhibiting interferon pathways in PK-15 cells. *Virus Research*, 286: 8. DOI: 10.1016/j.virusres.2020.198064.
48. **Sanson, R.L., Z.D.D. Yu, T.G. Rawdon, & M. van Andel.** Informing adaptive management strategies: Evaluating a mechanism to predict the likely qualitative size of Foot-and-Mouth Disease outbreaks in New Zealand using data available in the early response phase of simulated outbreaks. *Transboundary and Emerging Diseases*: 9. DOI: 10.1111/tbed.13820.
49. **Sareyyupoglu, B., C. Cokcaliskan, A. Coskuner, & V. Gulyaz** (2020). Determination of non-structural protein level for Turkey foot-and-mouth disease vaccine antigens during in-process. *Clinical and Experimental Vaccine Research*, 9(2): 97-101. DOI: 10.7774/cevr.2020.9.2.97.
50. **Severo, D.R.T., R.A. Werlang, A.P. Mori, K.R.A. Baldi, R.E. Mendes, S.R.S. Surian, A. Coldebella, B. Kramer, I.M. Trevisol, T.M.A. Gomes, & V.S. Silva.** Health profile of free-range wild boar (*Sus scrofa*) subpopulations hunted in Santa Catarina State, Brazil. *Transboundary and Emerging Diseases*: 13. DOI: 10.1111/tbed.13752.
51. **Singanaiiur, N.B., S. Nampanya, I. MacPhillamy, V. Soukvilay, C. Keokhamphet, R.D. Bush, S. Khounsy, N.K. Dhand, P. Windsor, & W. Vosloo** (2020). Serological evidence of Foot-and-mouth disease infection in goats in Lao PDR. *Frontiers in Veterinary Science*, 7: 11. DOI: 10.3389/fvets.2020.00544.
52. **Stenfeldt, C., M.R. Bertram, G.R. Smoliga, E.J. Hartwig, A.H. Delgado, & J. Arzt** (2020). Duration of contagion of *Foot-and-mouth disease virus* in infected live pigs and carcasses. *Frontiers in Veterinary Science*, 7: 12. DOI: 10.3389/fvets.2020.00334.
53. **Subramaniam, S., J.K. Biswal, J.K. Mohapatra, S.A. Khulape, M. Madhanmohan, & R.K. Singh.** Emergence of *Foot-and-mouth disease virus* serotype Asia1 group IX in India. *Archives of Virology*: 7. DOI: 10.1007/s00705-020-04766-5.
54. **Tsao, K., S. Sellman, L.M. Beck-Johnson, D.J. Murrieta, C. Hallman, T. Lindstrom, R.S. Miller, K. Portacci, M.J. Tildesley, & C.T. Webb** (2020). Effects of regional differences and demography in modelling foot-and-mouth disease in cattle at the national scale. *Interface Focus*, 10(1): 13. DOI: 10.1098/rsfs.2019.0054.
55. **Tuncer-Goktuna, P., C. Cokcaliskan, A. Arslan, N. Tascene, E.A. Uzun, C. Gunduzalp, G.N. Balci, O. Kara, & V. Gulyaz.** Monitoring the performance of foot-and-mouth disease vaccines prepared against local strains in the face of antigenic evolution in the field. *Transboundary and Emerging Diseases*: 8. DOI: 10.1111/tbed.13726.


56. **Ularamu, H.G., D.J. Lefebvre, A. Haegeman, Y.S. Wungak, D.O. Ehizibolo, D.D. Lazarus, A.R. De Vleeschauwer, & K. De Clercq** (2020). Complex circulation of *Foot-and-mouth disease virus* in Cattle in Nigeria. *Frontiers in Veterinary Science*, 7: 11. DOI: 10.3389/fvets.2020.00466.
57. **Visser, L.J., C. Aloise, K.N. Swatek, G.N. Medina, K.M. Olek, H.H. Rabouw, R.J. de Groot, M.A. Langereis, T. de los Santos, D. Komander, T. Skern, & F.J.M. van Kuppeveld** (2020). Dissecting distinct proteolytic activities of FMDV L(pro) implicates cleavage and degradation of RLR signaling proteins, not its deISGylase/DUB activity, in type I interferon suppression. *Plos Pathogens*, 16(7): 27. DOI: 10.1371/journal.ppat.1008702.
58. **Wong, C.L., C.Y. Yong, H.K. Ong, K.L. Ho, & W.S. Tan** (2020). Advances in the diagnosis of Foot-and-Mouth Disease. *Frontiers in Veterinary Science*, 7: 24. DOI: 10.3389/fvets.2020.00477.
59. **Xie, Y.L., H.Y. Chang, Z.Y. Li, & Y.M. Zhang** (2020). Adenovirus-vectored capsid proteins of the serotype a *Foot-and-Mouth Disease virus* protect guinea pigs against challenge. *Frontiers in Microbiology*, 11: 9. DOI: 10.3389/fmicb.2020.01449.
60. **Xu, H., Y.L. Niu, W.M. Hong, W.X. Liu, X.X. Zuo, X. Bao, C.M. Guo, Y. Lu, & B.H. Deng** (2020). Development of a water-in-oil-in-water adjuvant for foot-and-mouth disease vaccine based on ginseng stem-leaf saponins as an immune booster. *Comparative Immunology Microbiology and Infectious Diseases*, 71: 8. DOI: 10.1016/j.cimid.2020.101499.
61. **Yang, D.C., C. Sun, R.Y. Gao, H.W. Wang, W.M. Liu, K.W. Yu, G.H. Zhou, B. Zhao, & L. Yua** (2020). A temperature-dependent translation defect caused by internal ribosome entry site mutation attenuates *Foot-and-Mouth Disease virus*: implications for rational vaccine design. *Journal of Virology*, 94(16): 21. DOI: 10.1128/jvi.00990-20.
62. **Yeo, S., M. Yang, M. Nyachoti, R. Rauh, J.D. Callahan, & C. Nfon** (2020). Detection of *Foot-and-Mouth Disease virus* in swine meat juice. *Pathogens*, 9(6): 11. DOI: 10.3390/pathogens9060424.
63. **Yuan, H., N. Li, P.H. Li, X.W. Bai, P. Sun, H.F. Bao, X.H. Gong, X.Q. Ma, Y.M. Cao, K. Li, Y.F. Fu, J. Zhang, D. Li, Y.L. Chen, J. Zhang, Z.J. Lu, & Z.X. Liu**. Modification of the second translation initiation site restricts the replication of *Foot-and-mouth disease virus* in PK-15 cells. *Applied Microbiology and Biotechnology*: 12. DOI: 10.1007/s00253-020-10810-w.
64. **Zahid, M.N., M.A. Shahid, H.M. Imran, M. Oneeb, M. Ahmed, Z.U. Rehman, N. Arooj, & T. Yaqub** (2020). Integrins and heparan sulfate play crucial role in pathogenesis of *Foot-and-Mouth Disease virus*. *Pakistan Veterinary Journal*, 40(3): 403-406. DOI: 10.29261/pakvetj/2020.016.
65. **Zhu, J.J., C. Stenfeldt, E.A. Bishop, J.A. Canter, M. Eschbaumer, L.L. Rodriguez, & J. Arzt** (2020). Mechanisms of maintenance of Foot-and-mouth disease virus persistence inferred from genes differentially expressed in nasopharyngeal epithelia of virus carriers and non-carriers. *Frontiers in Veterinary Science*, 7: 20. DOI: 10.3389/fvets.2020.00340.

Annex 3: Vaccine recommendations

This report provides recommendations of FMDV vaccines to be included in antigen banks. These outputs are generated with a new tool (called PRAGMATIST) that has been developed in partnership between WRLFMD and EuFMD. These analyses accommodate the latest epidemiological data collected by the OIE FAO FMD Laboratory Network regarding FMDV lineages that are present in different *source regions* (see Table 1 in Section 3.9, above), as well as available *in vitro*, *in vivo* and field data to score the ability of vaccines to protect against these FMDV lineages.

Vaccine Antigen Prioritisation: Europe

October 2020



NB: Analyses uses best available data, however there are gaps in surveillance and vaccine coverage data

Please contact WRLFMD or EuFMD for assistance to tailor these outputs to other geographical regions. NB: Vaccine-coverage data presented is based on available data and may under-represent the true performance of individual vaccines.

Annex 4: Brief round-up of EuFMD and WRLFMD activities

Open Session of the EuFMD OS20

"Livelihoods @ risk in a FASTER world"

Held virtually in 4 sessions, beginning on 8 Dec 2020. There is no cost for registration. Plan to join us!

The OS20 will be organized in virtual sessions focused on animal mobility for FAST risk mapping (8 Dec), addressing risk change and forecast (10 Dec), vaccine security and critical resources for emergency management (15 Dec), and resilience to long-term FAST crises (17 Dec).

Detailed information is available at: <https://www.eufmd.info/os20faster>

Courses

- EuFMD's open access online courses provide convenient self-paced training which you may study anytime, anywhere, free of charge. There are currently 4 courses in English and 1 in Arabic:
 - Introduction to Foot-and-Mouth Disease
 - What is the Progressive Control Pathway?
 - Public Private Partnerships in the Veterinary Domain
 - Introduction to the Progressive Control Pathway

<https://eufmdlearning.works/mod/page/view.php?id=13130>

- The WRLFMD residential training course on FMD diagnostics (<https://www.pirbright.ac.uk/instructor-led-training/diagnosis-foot-and-mouth-disease>) scheduled for May 2020 has been postponed.
- November 2020: V-learning course on FMD diagnostics:

The 2020 edition of the **online FMD Laboratory Investigation Training Course** will take place in **November**. It has been developed by the FMD World Reference Laboratory at the Pirbright Institute, working in partnership with the European Commission for the Control of Foot-and-Mouth Disease, Food and Agriculture Organization of the United Nations. The course is designed for personnel working in national FMD laboratories and will provide training on:

- leading effective sample collection;
- procedures and interpretation of diagnostic tests for FMD virus and antibodies to FMD virus;
- advanced techniques for further characterization of FMD virus including sequencing and vaccine matching tests;
- submission of samples to reference laboratories;
- key principles of biosecurity and biosafety measures to be carried out in an FMD laboratory.

The training will be conducted in **English**. It is a tutored online course and participants will interact with Pirbright and EuFMD experts during two live webinars and an online discussion forum. The course involves **14 hours of study over a four-week period**, starting on 5 November 2020. Please find attached full details.

Places are available for self-registration on this course. Kindly note that there are limited number of places for this training and the selection of candidates will be made at the sole discretion of the EuFMD team. Participation in this training course is free of charge. Please note **that participants must be working in a laboratory involved in FMD diagnostics to take the course.**

[Click here to complete the application form.](#)

The deadline for nominations and applications is **28 October 2020.**



FMD LABORATORY INVESTIGATION
Training Course

This course is aimed at those working in national or regional foot-and-mouth disease laboratories and involved in carrying out or managing laboratory testing activities.

The course covers the full range of activities carried out by FMD laboratories from supervising collection of diagnostic samples through to advanced laboratory testing procedures, biosafety and quality assurance.

Participants will learn to

- Interact with field staff and guide them in collection and submission of appropriate, quality diagnostic samples;
- Select appropriate diagnostic tests to detect FMD virus and FMD virus-specific antibodies, and interpret the results of these tests;
- Describe the principles of accurate virus detection test methods and assays used for serology;
- Outline techniques for further characterization of FMD virus including genomic sequencing and vaccine matching tests.
- Explain the importance and basic principles of laboratory Quality Assurance.

> The course involves 14 hours of interactive virtual-learning content over a four week period.

> The course provides a unique opportunity to interact with your colleagues in FMD laboratories around the world.

> The EuFMD and the World Reference Laboratory for foot-and-mouth disease (WRLFMD), based at The Pirbright Institute, have partnered to produce this online training course.

euofmd European Commission for the control of foot-and-mouth disease
FAST Foot-and-mouth And Similar Transboundary animal diseases
velearning eufmd virtual learning
SPiRE Sharing Pirbright's Expertise
Hold-FAST Strategy Plan

VIRTUAL LEARNING COURSE - VIRTUAL LEARNING COURSE - VIRTUAL LEARNING COURSE

Podcasts

We have a constantly updated series of short podcasts relating to the FAST world, available here: <http://www.fao.org/eufmd/resources/podcasts/en/>

Meetings

The third GF-TADs FMD Roadmap Meeting (RMM) for Southern Africa will be held virtually on the 2 to the 5 of November 2020 in collaboration with the Southern African Development Community (SADC) Secretariat.


The first virtual meetings with the regional advisory groups (RAG) from Middle East (ME) and South Asian Association for Regional Cooperation (SAARC) will be held on the 18 November and 2 December respectively, in collaboration with the GF-TADs FMD WG partners.

Proficiency test scheme organised by WRLFMD

Sample panels for the Phase XXXII exercise are ready for dispatch and are beginning shipped to international laboratories as flights begin to resume after the COVID-19 crisis (see table below for a summary of the current status of the exercise).

Status	Number of Labs
Invitations	72
Responses	51
Declined to take part	3
Paperwork in progress	12
Panels shipped	31

We will write to inform participating laboratories about any other changes that may be required to accommodate these events, and please feel free to contact WRLFMD if you have any questions.



Funded by the
European Union



Biotechnology and
Biological Sciences
Research Council


Department
for Environment
Food & Rural Affairs


THE
Pirbright
INSTITUTE



fao.eufmd.org
eufmdlearning.works
eufmd.info
eufmd@fao.org

Hold-FAST tools

GET PREPARED, E-learning, FMD-PCP, EuFMDiS, Pragmatist, Impact Risk Calculator, Virtual Learning Center, SMS Disease reporting, Global Vaccine Security, Outbreak Investigation app, PCP-Support Officers, PCP Self-Evaluation tool, AESOP, Telegram, Whatsapp, Quarterly Global Reports, Real Time Training.

EuFMD Committees

Executive Committee, Standing Technical Committee, Special Committee for Surveillance and Applied Research (SCSAR), Special Committee on Biorisk Management (SCBRM), Tripartite Groups.